All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The EMA grants BP1001 Orphan Drug Designation for AML
Bookmark this article
In November 2016, the European Medicines Agency’s (EMAs) Committee for Orphan Medicinal Products (COMP) granted Orphan Drug Designation for BP1001 (prexigebersen) for the treatment of Acute Myeloid Leukemia (AML).
BP1001 is a novel liposome-incorporated antisense oligodeoxynucleotide targeted against the Growth factor receptor-bound protein 2 (Grb2) mRNA. BP1001 binds to and blocks Grb2 mRNA thus preventing Grb2 expression. Grb2 is involved in growth signalling pathways and can contribute to increased cell proliferation in cancer cells1.
BP1001 is currently being explored in combination with Low Dose Ara C (LDAC) in a phase 2 study (NCT02781883) for previously untreated elderly AML patients who are ineligible for intensive induction therapy. BP1001 is also be investigated in phase 1 study (NCT01159028) in adult patients with recurrent AML.
- Liposome incorporated Grb2 anti-sense oligodeoxynucleotide. https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=681815. [Accessed 2017 Jan 27]
- GlobeNewswire. Bio-Path Announces Orphan Drug Designation in the European Union for BP1001 for the Treatment of Acute Myeloid Leukemia. https://globenewswire.com/news-release/2016/11/03/886253/0/en/Bio-Path-Announces-Orphan-Drug-Designation-in-the-European-Union-for-BP1001-for-the-Treatment-of-Acute-Myeloid-Leukemia.html. [Accessed 2017 Jan 27].
More about...
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox